Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Sibylle Loibl(Goethe University Frankfurt), Nadia Harbeck(Breast Center), Giuseppe Curigliano(European Institute of Oncology), H. Gamal‐El‐Din(Cairo University), Sergei Tjulandin, Meredith M. Regan(Dana-Farber Cancer Institute), Lajos Pusztai(Yale University), Philip Poortmans(University of Antwerp), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Sung‐Bae Kim(Ulsan College), Prudence A. Francis(Peter MacCallum Cancer Centre), Carsten Denkert(Philipps University of Marburg), Valentina Guarneri(Istituto Oncologico Veneto), Dario Trapani(Harvard University), B. Xu(Henan University of Traditional Chinese Medicine), Maria João Cardoso(Champalimaud Foundation), Ann H. Partridge(Dana-Farber Cancer Institute), Eva Maria Fallenberg(TUM Klinikum), Wolfgang Janni(Grace (United States)), David Krug(University Hospital Schleswig-Holstein), Lisa A. Carey(University of North Carolina at Chapel Hill), Harold J. Burstein(Dana-Farber Cancer Institute), Sudeep Gupta(Homi Bhabha National Institute), Charles E. Geyer(Magee-Womens Hospital), Sandra M. Swain(Georgetown University), Karen A. Gelmon(University of British Columbia), Jonas Bergh(Karolinska Institutet), Lucia Del Mastro(Ospedale Policlinico San Martino), Monica Morrow(Memorial Sloan Kettering Cancer Center), Joseph A. Sparano(Tisch Cancer Institute), Andrew Tutt(Institute of Cancer Research), Shaheenah Dawood(Mediclinic City Hospital), Masakazu Toi(Mukogawa Women's University), Miguel Martín(Hospital General Universitario Gregorio Marañón), Carlos H. Barrios(Eastern Cooperative Oncology Group), Icro Meattini(Azienda Ospedaliero-Universitaria Careggi), Thomas Bachelot(Centre Léon Bérard), Shani Paluch–Shimon(Hebrew University of Jerusalem), Tanja Španić(Unknown), Fabrice André(Inserm)
Cited by 830
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k